'Little purple pill' is under microscope

Oct 11, 2010 By Maura Lerner

Dr. Marcus Thygeson once wrote his patients countless prescriptions for heartburn drugs such as Prevacid, Prilosec and Nexium -- the "little purple pills" of TV ads.

But several months ago, when his own doctor advised him to start taking the , he refused. "It was all I could do to get out of the office without a prescription," he said.

The Twin Cities gastroenterologist has come to see the popular pills as a symbol of the excesses of modern medicine -- a powerful medication "handed out like water" in his words, amid mounting evidence that it may do many people more harm than good.

"It's a drug we've become very cavalier about," says Thygeson, president of the Center for Healthcare Innovation at Allina Hospitals & Clinics.

"Now it's like front-line therapy if you so much as belch."

The heartburn drugs, known as proton-pump inhibitors (PPIs), are designed to reduce the body's ability to pump acid into the stomach.

Today, they are among the nation's best-selling medications, with more than 119 million written last year, in addition to over-the-counter sales. Experts have called them a godsend for ailments like acid reflux, a major cause of heartburn.

Yet there's a growing consensus that millions of people are taking the pills needlessly, or far longer than necessary, wasting billions of dollars and in some cases triggering significant side effects.

Some skeptics even dare to ask why so many Americans are taking pills, which can cost up to $200 a month, to control digestive problems that can be tied to their own bad habits, particularly at the dinner table.

"I'm not blaming patients -- it's the path of least resistance," said Dr. Greg Plotnikoff, an internist at Abbott Northwestern's Penny George Institute for Health and Healing in Minneapolis. Fixing the underlying problem, he said, may require losing weight, avoiding certain foods or other lifestyle changes. A pill can seem like an easy alternative.

"When I was a resident, I was told it was a quick and easy answer to everything, and it had no side effects, and insurance was willing to pay for it," Plotnikoff said.

In the past few years, though, scientists have raised concerns about long-term side effects, such as bone fractures and pneumonia. One study in 2009 even found that the drugs, when stopped abruptly, can cause the very symptoms they were designed to prevent.

The drug manufacturers and some leading experts have disputed those findings. But insurers and doctors alike are starting to have second thoughts.

"When you put a patient on a PPI, you're essentially setting them up to be on it for a lifetime," said Thygeson. "I think we need to back away from those drugs."

Bernice Koniar had every reason to feel grateful when her doctor started her on heartburn medication. She had just learned she had gastroesophageal reflux disease (GERD), a cause of chronic acid indigestion and all-around misery.

And there was nothing more effective for that condition, experts said, than this new class of acid-suppressing drugs.

Actually, they were the second big breakthrough. The first, cimetidine (Tagamet), revolutionized treatment by blocking acid production for short periods.

Then Prilosec, the first proton-pump inhibitor, made its debut in 1989.

"This drug was a miracle," said Dr. Robert Ganz, a Twin Cities gastroenterologist and associate professor at the University of Minnesota. It was remarkably effective for GERD, a condition that causes stomach acid to leak into the esophagus, which in turn can cause burning sensations, nausea and even permanent damage.

In the past, he said, doctors could offer little beyond temporary relief (Tums or Mylanta) or, for severe cases, surgery. "Without this drug, you'd have 20 million people going to surgery," he said. "This drug was one of the great pharmaceutical discoveries ... of all time."

It's now a certified blockbuster, with $13.6 billion in sales last year (more, counting over-the-counter sales).

Prilosec was approved for "short term treatment (4-8 weeks)" for most symptoms, according to its label. AstraZeneca, which makes Prilosec and Nexium, said its own studies showed that nine-tenths of acid reflux patients "successfully healed" in eight weeks.

But once the Food and Drug Administration gave its blessing, doctors were free to prescribe them for as long as they liked.

As a result, patients like Koniar, who lives in Minnetonka, Minn., have been taking the pills for years. Now 66, she weaned herself off the medication about a month ago. "I was just taking a drug for something that didn't exist anymore," she said last month.

In recent years, several studies have suggested that many people are taking the drug for no apparent reason. In one Michigan hospital, researchers reviewed patient charts in 2005 and concluded that 60 percent were started on acid-suppressing drugs with no valid explanation.

In May, an editorial in the Archives of Internal Medicine claimed that 53 to 69 percent of the prescriptions for acid suppressors are "for inappropriate indications."

Dr. David Peura, an industry consultant and former president of the American Gastroenterological Association, readily admits that the drugs are overused. But he said that's partly because doctors are reluctant to take patients off medicine if it seems to be working. "One of the first rules in medicine is, don't poke a skunk," said Peura, a retired academic and researcher in Virginia. "That's why I think a lot of people are probably on the medicine who probably don't need it."

At the same time, he and others say, the reasons for using the drugs have expanded. They're widely used to prevent ulcers in vulnerable patients, such as the elderly who take daily aspirin. Some doctors even use them to diagnose patients with vague symptoms. Instead of ordering a diagnostic procedure, such as an endoscopy, they might give the patient the drug to see if they improve, said Ganz, a partner in Minnesota Gastroenterology. "What's the downside?" he asks. "I might make you feel better. I'm saving you an invasive test." And if it works, "I'm a hero."

Critics, though, aren't so sure. In the past few years, studies have linked the drugs to an increased risk of bone fractures, pneumonia and an intestinal infection called C. difficile. There's also concern the medication may interfere with a heart drug, Plavix.

And last year, researchers in Denmark found that healthy volunteers who took the drugs for eight weeks experienced heartburn and other symptoms when they abruptly stopped. It's what scientists call the "rebound effect."

The theory is that when someone stops taking the drug, the acid production system kicks into overdrive, causing even harsher symptoms.

"It's the best business model ever," says Plotnikoff, a longtime critic.

"The more you take it, the more you need it." His solution: Wean patients slowly.

Industry scientists, as well as some national experts, downplay concerns about the rebound effect and say the studies on bone fractures and other side effects are flawed and inconclusive.

"The concern about acid rebound is really not a significant concern," said Dr. David Johnson, chief of gastroenterology at Eastern Virginia School and a consultant to drugmakers. He said if symptoms recur, it's probably due to the underlying condition.

He also said the evidence of side effects is weak and contradictory. His own review, published in April, found no evidence that the drugs interfere with Plavix, for example.

AstraZeneca, one of the largest manufacturers, did not respond to requests for comment.

However, an official at Takeda Pharmaceuticals, which makes Prevacid and Dexilant, said the company takes the concerns seriously. "The data are far from clear," said medical director Dr. Gilles Delecoeuillerie. As a result, the company is conducting its own tests on the reported side effects.

But concerns about overuse and safety are starting to change attitudes, even if the risks are low, said Peura, who has studied the drugs extensively. "The paradigm has sort of shifted," he said. "We recognize that we should probably be taking people off the medication, or at least lowering the dose."

But as someone who's been taking the pills himself for years, he knows that may not be easy. "They made people really feel good for the first time," he said. And doctors are under more pressure than ever to find a quick fix for patient complaints. "If we can deal with that with a pill, we'll do it."

Explore further: Investigational drug improves sleep disorder among the blind

4.4 /5 (7 votes)
add to favorites email to friend print save as pdf

Related Stories

FDA says heartburn drugs can interfere with Plavix

Nov 17, 2009

(AP) -- Federal health officials said Tuesday a popular variety of heartburn medications can interfere with the blood thinner Plavix, a drug taken by millions of Americans to reduce risks of heart attack ...

Study shows zinc salts offer rapid relief from gastric reflux

Aug 24, 2010

(PhysOrg.com) -- In a study that could revolutionize how millions of people are treated for painful gastric acid-related diseases, a team led by Yale School of Medicine researchers has shown that zinc salts offer rapid, prolonged ...

Aspirin, acid blocker a-day keeps GI bleeding

Aug 11, 2008

For patients with clogged heart arteries who take long-term, low-dose aspirin to prevent a cardiac event, adding a stomach acid-blocking drug to their daily routine has been shown to reduce their risk for upper gastrointestinal ...

Recommended for you

Protalix signs supply deal with Brazilian govt

2 hours ago

Shares of Protalix BioTherapeutics Inc. jumped in premarket trading Wednesday after the drug developer announced a deal that requires the Brazilian government to buy at least $280 million of the company's Gaucher disease ...

EU fines pharma firms over generics delay (Update)

2 hours ago

(AP)—The European Union has fined Danish pharmaceuticals multinational Lundbeck and several other producers a combined 146 million euros ($195 million) for delaying the market entry of cheaper generic alternatives ...

Investigational drug improves sleep disorder among the blind

Jun 17, 2013

An investigational new drug significantly improved a common and debilitating circadian rhythm sleep disorder that frequently affects people who are completely blind, a multicenter study finds. The results were presented Monday ...

US: 'Pay to delay' generic drugs can be illegal (Update)

Jun 17, 2013

The Supreme Court ruled Monday that deals between pharmaceutical corporations and their generic drug competitors, which government officials say keep cheaper forms of medicine off the market, can be sometimes be illegal and ...

Medications to prevent clots not reaching some patients

Jun 14, 2013

Researchers at Johns Hopkins report that hospitalized patients do not receive more than one in 10 doses of doctor-ordered blood thinners prescribed to prevent potentially lethal or disabling blood clots, a decision they say ...

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

WirelessPhil
1 / 5 (1) Oct 11, 2010
It wasn't Prilosec you idiot!
It was Viagra!

Know what?
I'm canceling my subscription to your BS news!
Roj
5 / 5 (1) Oct 12, 2010
I'm canceling my subscription to your BS news!
Trolls are not allowed subscriptions.

More news stories

Antioxidant shows promise in Parkinson's disease

Diapocynin, a synthetic molecule derived from a naturally occurring compound (apocynin), has been found to protect neurobehavioral function in mice with Parkinson's Disease symptoms by preventing deficits in motor coordination.

Paralysed with fear: The story of polio

Thanks to vaccination, polio has been pushed to the brink of extinction – but can we finish the job? This is one of the big questions which a Bristol academic addresses in his new book, published next week.

EUROnu project recommends building Neutrino Factory

(Phys.org) —The European Union's Seventh Framework Programme, EUROnu, has submitted its findings to a panel at CERN. Charged with choosing a project to study the nature of matter and antimatter, the project ...

'Ugly' finding: Unattractive workers suffer more

People who are considered unattractive are more likely to be belittled and bullied in the workplace, according to a first-of-its-kind study led by a Michigan State University business scholar.